SupplementsPeter Attia's Evidence Framework for Evaluating Peptide Claims
Peter Attia dedicates this episode to cutting through the noise surrounding peptides — compounds increasingly marketed for muscle growth, injury recovery, and longevity. Rather than blanket endorsement or rejection, he introduces a five-question evaluation framework and a three-tier evidence classification system. He then applies these tools to specific peptides: BPC-157, which he finds lacks clear mechanisms and human evidence, and CJC-1295, where biological activity does not automatically translate to meaningful clinical benefit. He addresses why testimonials, compounding pharmacy prescriptions, and third-party testing cannot substitute for controlled trials, and why gray-market versions of even FDA-approved peptides carry distinct risks. The episode closes with a call for falsifiable claims and evidence-first standards before widespread peptide use becomes normalized.
